HOUSTON--(BUSINESS WIRE)--Memgen, Inc., a clinical-stage biotechnology company developing potentially life-saving cancer immunotherapies, announced that Kevin M. Coveney, CPA, has been appointed Chief Financial Officer.
“We are delighted to have Kevin join the Memgen leadership team,” said Gregory Brown, M.D., Chief Executive Officer of Memgen. “Kevin’s broad experience in financing, strategy development and execution, as well collaboration with academic researchers and biopharma partners, make him the ideal addition to our team as we begin the clinical trial of MEM-288 for non-small lung cancer and other solid tumors.”
Mr. Coveney has extensive experience in biotechnology accounting and finance, internal controls and value creation efforts. Prior to Memgen, Mr. Coveney was chief financial officer of Q-State Biosciences, a preclinical biotechnology company. Earlier, Mr. Coveney was senior vice president of finance, human resources and information technology at Vedanta Biosciences, a clinical stage company advancing microbiome treatments for C. difficile, food allergies and oncology. He also held senior finance positions at Berg Health, a clinical stage developer of oncology treatments using an artificial intelligence platform. Prior to entering the biotechnology industry, Mr. Coveney, a former audit partner, worked for many years in the life science audit practices of major accounting firms including EY and BDO Seidman.
“It’s an exciting time to be joining Memgen,” noted Mr. Coveney. “With the clinical trial of MEM-288 launching by year end, the company has moved to a new level. I’m thrilled to join the leadership team to help develop MEM-288 and other cancer immunotherapies to provide new hope to cancer patients.”
About Memgen
Memgen is a clinical-stage biopharmaceutical company developing cancer immunotherapies to harness the power of the immune system to cure cancer. Its first-in-class immuno-oncology therapeutic candidates leverage the power of CD40 ligand, a uniquely powerful immune modulator. In tests in patients, the company’s proprietary CD40 ligand transgene has been shown to elicit powerful, antigen-specific, anti-tumor immune responses across a broad range of tumor types, without the toxicity typically seen by other approaches to activating CD40. Working with collaborators at top cancer research institutions, Memgen is advancing cancer treatments for patients who do not respond to currently available therapeutic options. For more information, visit www.memgenbio.com.
